| Authors: |
Jha R; Autolus Therapeutics, London W12 7FP, U.K.; Research Department of Haematology, UCL Cancer Institute, University College London, London WC1E 6DD, U.K., Kinna A; Autolus Therapeutics, London W12 7FP, U.K., Hotblack A; Research Department of Haematology, UCL Cancer Institute, University College London, London WC1E 6DD, U.K., Bughda R; Autolus Therapeutics, London W12 7FP, U.K., Bulek A; Autolus Therapeutics, London W12 7FP, U.K., Gannon I; Autolus Therapeutics, London W12 7FP, U.K., Ilca T; Autolus Therapeutics, London W12 7FP, U.K., Allen C; Autolus Therapeutics, London W12 7FP, U.K., Lamb K; Autolus Therapeutics, London W12 7FP, U.K., Dolor A; Autolus Therapeutics, London W12 7FP, U.K., Scott I; Autolus Therapeutics, London W12 7FP, U.K., Parekh F; Autolus Therapeutics, London W12 7FP, U.K., Sillibourne J; Autolus Therapeutics, London W12 7FP, U.K., Cordoba S; Autolus Therapeutics, London W12 7FP, U.K., Onuoha S; Autolus Therapeutics, London W12 7FP, U.K., Thomas S; Autolus Therapeutics, London W12 7FP, U.K., Ferrari M; Autolus Therapeutics, London W12 7FP, U.K., Pule M; Autolus Therapeutics, London W12 7FP, U.K.; Research Department of Haematology, UCL Cancer Institute, University College London, London WC1E 6DD, U.K. |